CSF biomarkers in Alzheimer’s disease: are the hypotheses more dynamic than the biomarkers?

Abbreviated title: CSF biomarker dynamics in AD

Petra E. Spies, MD,¹ Marcel M. Verbeek, PhD,²,³ Marcel G.M. Olde Rikkert, MD, PhD,¹
Jurgen A.H.R. Claassen, MD, PhD¹

Radboud University Nijmegen Medical Centre, Donders Institute for Brain, Cognition and Behaviour, and Alzheimer Centre Nijmegen, The Netherlands

¹Department of Geriatric Medicine, ²Department of Laboratory Medicine, ³Department of Neurology

Corresponding author:
P.E. Spies, MD, Department of Geriatric Medicine, 925, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. Tel.: +31 24 361 6772, fax: +31 24 361 7408, e-mail: p.spies@ger.umcn.nl

Alternate corresponding author:
J.A.H.R. Claassen, MD, PhD, Department of Geriatric Medicine, 925, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. Tel.: +31 24 361 6772, fax: +31 24 361 7408, e-mail: j.claassen@ger.umcn.nl

This research was not funded.

Number of words: 720
Biomarkers for Alzheimer’s disease (AD) such as hippocampal atrophy and abnormal concentrations of cerebrospinal fluid (CSF) amyloid β42 (Aβ42), phosphorylated tau181 (p-tau) and total tau (t-tau) have become established tools in the diagnostic work-up of patients suspected of dementia. Recently, AD research has seen a shift in focus towards the prodromal and preclinical stages of this disease, at the same time creating a shift in emphasis from clinical criteria towards biomarkers that represent core features of AD. The CSF biomarkers Aβ42, p-tau and t-tau are promising candidates, as they reflect the neuropathologic features of AD and research indicates they become abnormal early in the disease process. However, data are currently lacking regarding the exact timing of these biomarkers becoming abnormal, and the order in which these events happen. Longitudinal studies to elucidate the dynamics of this process are still ongoing, but several hypothetical models have been proposed. These models are relevant in providing a framework for further research, for example to establish a paradigm in which biomarker changes over time could become surrogate end-points in disease modification trials. In addition, biomarker dynamics might provide information on disease stage and progression once these models have been confirmed.

An interesting feature that these models have in common is that they make a clear distinction between the moment that CSF Aβ42 becomes abnormal and the moment that CSF tau becomes abnormal. Amyloid deposition (resulting in reduced levels of CSF Aβ42) is suggested to be the earliest event, occurring long before cognitive symptoms are apparent, and plateauing early in the disease. Tau on the other hand is suggested to become abnormal much later, when clinical symptoms are already present, and to continue to increase in patients who progress from mild cognitive impairment (MCI) to moderate and severe dementia.1,2

We question this distinction in timing between amyloid and tau. To illustrate that these models can be challenged by empirical data, we present a case of early-onset AD with the
longest follow-up of CSF biomarkers reported in the literature. During the nine years between the earliest clinical manifestation and advanced dementia, we noted no essential changes in CSF Aβ_{42}, p-tau and t-tau. At age 53, this man presented with a mild memory disorder objectified by neuropsychological testing. Neuroimaging (CT cerebrum) was normal, but CSF analysis showed abnormal results: 294 pg/ml (reference value >500 pg/ml), phosphorylated tau_{181} (p-tau) 141 pg/ml (<85 pg/ml), and t-tau 660 pg/ml (<350 pg/ml).³ No interference with activities of daily living was established and MCI was diagnosed. Over the next four years he gradually progressed – confirmed by repeated neuropsychological evaluation – to a diagnosis of probable AD, Clinical Dementia Rating (CDR) 1. Nine years after first contact, we re-evaluated this patient, now progressed to CDR 2, with marked brain atrophy on CT. Lumbar puncture showed Aβ_{42} 399 pg/ml, p-tau 108 pg/ml, t-tau 655 pg/ml.

This case suggests that either there is no delay between changes in CSF Aβ_{42}, p-tau and t-tau, or that the change in tau occurs much earlier than suggested, that is, already in the preclinical stage. Studies in MCI patients support this by showing that both CSF Aβ_{42} and tau are already abnormal in those patients who progressed to AD at follow up.⁴ We observed no further decrease in Aβ_{42} or increase in p-tau or t-tau during disease progression in this case. This observation is supported by the few longitudinal studies performed so far in MCI and AD patients – albeit with a much shorter follow up of 2 years – that show a remarkable stability of CSF Aβ_{42} and t-tau concentrations.³⁵ This argues against the assumption that a change in pathological direction of these biomarkers could be of use as surrogate markers to reflect progression of disease.

This case questions models built largely on cross-sectional data. Inter-individual differences in progression rate and disease duration at diagnosis make cross-sectional studies unsuitable for inferences about the timing and order of events. Longitudinal studies covering the full spectrum of the disease, with measurement of imaging and biochemical markers, will
be needed before a valid temporal model can be constructed. We speculate, however, that such studies will fail to demonstrate a clear distinction between the timing of Aβ42 and tau becoming abnormal. Likely, they will demonstrate a lack of relevant CSF Aβ42, p-tau and t-tau changes over time in the transition from early MCI to AD.
Acknowledgements

Conflicts of Interest

Marcel Verbeek is a consultant for Schering-Plough and is supported by a grant from the Organisation for Scientific Research (NWO/ZonMW, Vidi program, no. 917.46.331). Marcel Olde Rikkert is a consultant for Schering-Plough, Janssen-Cilag, and Numico and is supported by grants from the Netherlands Organisation for Health Research and Development (ZonMw). Jurgen Claassen is a consultant for Novartis and Janssen-Cilag and is supported by a grant from the Netherlands Heart Foundation and Internationale Stichting Alzheimer Onderzoek (ISAO).

Author’s Contributions

Concept and design: Petra Spies and Jurgen Claassen; data collection: Petra Spies and Marcel Verbeek; analysis and interpretation of data: all authors; preparation of the manuscript: all authors. All authors approved the final version.

Sponsor’s Role

This research was not funded.
References


